PMC:7195088 / 31118-33620 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T34","span":{"begin":38,"end":46},"obj":"Body_part"},{"id":"T35","span":{"begin":101,"end":103},"obj":"Body_part"},{"id":"T36","span":{"begin":117,"end":119},"obj":"Body_part"},{"id":"T37","span":{"begin":217,"end":225},"obj":"Body_part"},{"id":"T38","span":{"begin":1580,"end":1593},"obj":"Body_part"},{"id":"T39","span":{"begin":1580,"end":1591},"obj":"Body_part"},{"id":"T40","span":{"begin":1616,"end":1624},"obj":"Body_part"},{"id":"T41","span":{"begin":1887,"end":1891},"obj":"Body_part"},{"id":"T42","span":{"begin":1887,"end":1889},"obj":"Body_part"},{"id":"T43","span":{"begin":2476,"end":2482},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A37","pred":"fma_id","subj":"T37","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma228738"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T24","span":{"begin":452,"end":457},"obj":"Body_part"},{"id":"T25","span":{"begin":513,"end":518},"obj":"Body_part"},{"id":"T26","span":{"begin":908,"end":913},"obj":"Body_part"},{"id":"T27","span":{"begin":2476,"end":2482},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":1381,"end":1387},"obj":"Phenotype"},{"id":"T31","span":{"begin":2259,"end":2268},"obj":"Phenotype"},{"id":"T32","span":{"begin":2343,"end":2348},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T161","span":{"begin":267,"end":275},"obj":"Disease"},{"id":"T162","span":{"begin":358,"end":366},"obj":"Disease"},{"id":"T163","span":{"begin":615,"end":623},"obj":"Disease"},{"id":"T164","span":{"begin":791,"end":799},"obj":"Disease"},{"id":"T165","span":{"begin":1052,"end":1060},"obj":"Disease"},{"id":"T166","span":{"begin":1370,"end":1387},"obj":"Disease"},{"id":"T167","span":{"begin":1381,"end":1387},"obj":"Disease"},{"id":"T168","span":{"begin":1392,"end":1400},"obj":"Disease"},{"id":"T169","span":{"begin":1679,"end":1687},"obj":"Disease"},{"id":"T170","span":{"begin":2025,"end":2033},"obj":"Disease"},{"id":"T171","span":{"begin":2250,"end":2258},"obj":"Disease"},{"id":"T172","span":{"begin":2259,"end":2268},"obj":"Disease"},{"id":"T173","span":{"begin":2399,"end":2411},"obj":"Disease"}],"attributes":[{"id":"A161","pred":"mondo_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A162","pred":"mondo_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A163","pred":"mondo_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0024880"},{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T172","span":{"begin":12,"end":21},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T173","span":{"begin":74,"end":82},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T174","span":{"begin":239,"end":242},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T175","span":{"begin":373,"end":378},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T176","span":{"begin":494,"end":498},"obj":"http://purl.obolibrary.org/obo/CLO_0001550"},{"id":"T177","span":{"begin":630,"end":635},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T178","span":{"begin":890,"end":893},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"},{"id":"T179","span":{"begin":1067,"end":1072},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T180","span":{"begin":1132,"end":1133},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T181","span":{"begin":1179,"end":1180},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T182","span":{"begin":1407,"end":1412},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T183","span":{"begin":1580,"end":1593},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T184","span":{"begin":1694,"end":1699},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T185","span":{"begin":2040,"end":2045},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T186","span":{"begin":2275,"end":2280},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T187","span":{"begin":2340,"end":2341},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T188","span":{"begin":2386,"end":2387},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T418","span":{"begin":48,"end":59},"obj":"Chemical"},{"id":"T419","span":{"begin":101,"end":103},"obj":"Chemical"},{"id":"T421","span":{"begin":117,"end":119},"obj":"Chemical"},{"id":"T423","span":{"begin":308,"end":319},"obj":"Chemical"},{"id":"T424","span":{"begin":373,"end":378},"obj":"Chemical"},{"id":"T425","span":{"begin":537,"end":548},"obj":"Chemical"},{"id":"T426","span":{"begin":553,"end":564},"obj":"Chemical"},{"id":"T427","span":{"begin":569,"end":580},"obj":"Chemical"},{"id":"T428","span":{"begin":586,"end":597},"obj":"Chemical"},{"id":"T429","span":{"begin":630,"end":635},"obj":"Chemical"},{"id":"T430","span":{"begin":737,"end":748},"obj":"Chemical"},{"id":"T431","span":{"begin":941,"end":952},"obj":"Chemical"},{"id":"T432","span":{"begin":958,"end":976},"obj":"Chemical"},{"id":"T433","span":{"begin":982,"end":994},"obj":"Chemical"},{"id":"T434","span":{"begin":999,"end":1010},"obj":"Chemical"},{"id":"T435","span":{"begin":1016,"end":1034},"obj":"Chemical"},{"id":"T436","span":{"begin":1067,"end":1072},"obj":"Chemical"},{"id":"T437","span":{"begin":1262,"end":1273},"obj":"Chemical"},{"id":"T438","span":{"begin":1294,"end":1305},"obj":"Chemical"},{"id":"T439","span":{"begin":1407,"end":1412},"obj":"Chemical"},{"id":"T440","span":{"begin":1503,"end":1514},"obj":"Chemical"},{"id":"T441","span":{"begin":1533,"end":1544},"obj":"Chemical"},{"id":"T442","span":{"begin":1694,"end":1699},"obj":"Chemical"},{"id":"T443","span":{"begin":1797,"end":1803},"obj":"Chemical"},{"id":"T444","span":{"begin":1849,"end":1860},"obj":"Chemical"},{"id":"T445","span":{"begin":1887,"end":1889},"obj":"Chemical"},{"id":"T447","span":{"begin":1901,"end":1911},"obj":"Chemical"},{"id":"T448","span":{"begin":1975,"end":1986},"obj":"Chemical"},{"id":"T449","span":{"begin":2040,"end":2045},"obj":"Chemical"},{"id":"T450","span":{"begin":2184,"end":2203},"obj":"Chemical"},{"id":"T451","span":{"begin":2184,"end":2193},"obj":"Chemical"},{"id":"T452","span":{"begin":2194,"end":2203},"obj":"Chemical"},{"id":"T453","span":{"begin":2207,"end":2217},"obj":"Chemical"},{"id":"T454","span":{"begin":2221,"end":2232},"obj":"Chemical"},{"id":"T455","span":{"begin":2275,"end":2280},"obj":"Chemical"}],"attributes":[{"id":"A418","pred":"chebi_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A419","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A420","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A421","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A422","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A423","pred":"chebi_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A424","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A425","pred":"chebi_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A426","pred":"chebi_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A427","pred":"chebi_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A428","pred":"chebi_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A429","pred":"chebi_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A430","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A431","pred":"chebi_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A432","pred":"chebi_id","subj":"T432","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A433","pred":"chebi_id","subj":"T433","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A434","pred":"chebi_id","subj":"T434","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A435","pred":"chebi_id","subj":"T435","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A436","pred":"chebi_id","subj":"T436","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A437","pred":"chebi_id","subj":"T437","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A438","pred":"chebi_id","subj":"T438","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A439","pred":"chebi_id","subj":"T439","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A440","pred":"chebi_id","subj":"T440","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A441","pred":"chebi_id","subj":"T441","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A442","pred":"chebi_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A443","pred":"chebi_id","subj":"T443","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A444","pred":"chebi_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A445","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A446","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A447","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A448","pred":"chebi_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A449","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A450","pred":"chebi_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A451","pred":"chebi_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A452","pred":"chebi_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A453","pred":"chebi_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A454","pred":"chebi_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A455","pred":"chebi_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T12","span":{"begin":2399,"end":2411},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-sentences","denotations":[{"id":"T244","span":{"begin":0,"end":116},"obj":"Sentence"},{"id":"T245","span":{"begin":117,"end":367},"obj":"Sentence"},{"id":"T246","span":{"begin":368,"end":417},"obj":"Sentence"},{"id":"T247","span":{"begin":418,"end":520},"obj":"Sentence"},{"id":"T248","span":{"begin":521,"end":624},"obj":"Sentence"},{"id":"T249","span":{"begin":625,"end":666},"obj":"Sentence"},{"id":"T250","span":{"begin":667,"end":720},"obj":"Sentence"},{"id":"T251","span":{"begin":721,"end":800},"obj":"Sentence"},{"id":"T252","span":{"begin":801,"end":852},"obj":"Sentence"},{"id":"T253","span":{"begin":853,"end":924},"obj":"Sentence"},{"id":"T254","span":{"begin":925,"end":1061},"obj":"Sentence"},{"id":"T255","span":{"begin":1062,"end":1111},"obj":"Sentence"},{"id":"T256","span":{"begin":1112,"end":1245},"obj":"Sentence"},{"id":"T257","span":{"begin":1246,"end":1401},"obj":"Sentence"},{"id":"T258","span":{"begin":1402,"end":1451},"obj":"Sentence"},{"id":"T259","span":{"begin":1452,"end":1469},"obj":"Sentence"},{"id":"T260","span":{"begin":1470,"end":1486},"obj":"Sentence"},{"id":"T261","span":{"begin":1487,"end":1688},"obj":"Sentence"},{"id":"T262","span":{"begin":1689,"end":1738},"obj":"Sentence"},{"id":"T263","span":{"begin":1739,"end":1832},"obj":"Sentence"},{"id":"T264","span":{"begin":1833,"end":2034},"obj":"Sentence"},{"id":"T265","span":{"begin":2035,"end":2084},"obj":"Sentence"},{"id":"T266","span":{"begin":2085,"end":2152},"obj":"Sentence"},{"id":"T267","span":{"begin":2153,"end":2269},"obj":"Sentence"},{"id":"T268","span":{"begin":2270,"end":2319},"obj":"Sentence"},{"id":"T269","span":{"begin":2320,"end":2502},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}